GlassScriptPhysician profile
Amy Clanton Boone
NPI 1740467281
$7,152.72
in general payments reported to CMS, 2019-2025
33 companies · $2,298 in 2025
The $2,298 reported for 2025 was more than what 96% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $1,073 · 2022: $911 · 2023: $1,468 · 2024: $1,403 · 2025: $2,298.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,092 · Education: $76.99.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,091.88 |
| Education | $76.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $2,093.67 | 2021-2025 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $1,065.51 | 2021-2025 | Xifaxan, Relistor, Plenvu |
| Ardelyx, INC. | $501.91 | 2023-2025 | Ibsrela |
| Janssen Biotech, INC. | $490.07 | 2021-2025 | Tremfya, Simponi Aria, Stelara |
| Pfizer INC. | $451.57 | 2021-2025 | |
| Takeda Pharmaceuticals U.S.A., INC. | $364.50 | 2021-2025 | Entyvio, Eohilia, Gattex |
| Gilead Sciences, INC. | $363.34 | 2021-2025 | Epclusa |
| Qol Medical, LLC | $253.66 | 2021-2025 | Sucraid |
| Nestle Healthcare Nutrition INC. | $237.81 | 2021-2022 | |
| Merck Sharp & Dohme LLC | $196.88 | 2021-2023 | Dificid |
| Braintree Laboratories, INC. | $150.17 | 2023-2025 | Sutab, Suflave |
| Madrigal Pharmaceuticals | $144.07 | 2024-2025 | Rezdiffra, Resmetirom |
| Genzyme Corporation | $116.95 | 2022-2025 | |
| Ipsen Biopharmaceuticals, INC | $87.20 | 2024-2025 | Iqirvo, Bylvay |
| Daiichi Sankyo INC. | $72.02 | 2022-2025 | Injectafer |
Show all 33 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ferring Pharmaceuticals INC. | $57.98 | 2024-2025 | Rebyota |
| Ironwood Pharmaceuticals, INC | $52.80 | 2021-2023 | Linzess |
| Boehringer Ingelheim Pharmaceuticals, INC. | $49.42 | 2023 | Cyltezo |
| Neuraxis, INC. | $46.98 | 2025 | |
| Intercept Pharmaceuticals, INC. | $45.78 | 2025 | |
| Redhill Biopharma INC. | $44.38 | 2021-2023 | Aemcolo, Talicia, Movantik |
| Boston Scientific Corporation | $42.89 | 2025 | Watchman Flx |
| Celgene Corporation | $33.71 | 2022 | |
| Regeneron Healthcare Solutions, INC. | $30.71 | 2025 | Dupixent |
| Fresenius Kabi USA, LLC | $25.15 | 2024 | Idacio |
| Amgen INC. | $22.83 | 2025 | Uplizna |
| Sandoz INC. | $21.68 | 2024 | Hyrimoz |
| Biocon Biologics INC | $19.25 | 2024 | Hulio |
| Lilly USA, LLC | $18.76 | 2025 | Omvoh |
| Mylan Institutional INC. | $17.75 | 2023 | Hulio |
| Janssen Scientific Affairs, LLC | $15.28 | 2025 | Tremfya |
| Aimmune Therapeutics, INC. | $14.32 | 2025 | Zenpep |
| Phathom Pharmaceuticals, INC. | $3.72 | 2025 | Voquezna |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Amy Boone listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.